Polyprogmasia influence on the development of complications in elderly and senile people with low creatinine clearance
- Authors: Kondrakhin A.P.1,2, Maksimov M.L.3,4,5, Sychev I.V.5
-
Affiliations:
- State Budgetary Institution of Healthcare of Moscow "Hospital for War Veterans No. 2 of the Moscow City Health
- Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation Department
- Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
- Kazan State Medical Academy - branch of the Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation
- Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation
- Issue: Vol 27, No 12 (2024)
- Pages: 94-99
- Section: Medical chemistry
- URL: https://journals.eco-vector.com/1560-9596/article/view/643435
- DOI: https://doi.org/10.29296/25877313-2024-12-12
- ID: 643435
Cite item
Open Access
Access granted
Abstract
Introduction. This paper highlights the issues of polypragmasia and its impact on clinical outcomes of oral anticoagulants.
Objective. To report the clinical outcomes of oral anticoagulants in patients with polypragmasia.
Material and methods. 503 patients taking oral anticoagulants along with other drugs were included in the study.
Results. according to the results of the study it was found that polypragmasia is a significant factor of POAC-related complications. The factors of drug withdrawal or complications related to POAC administration were: obesity of 2nd and 3rd degree, advanced age, chronic kidney disease stage C3b and C4. The above factors are the direct factors of polypragmasy, which in itself reduces adherence to POAC, in addition to that POAC withdrawal was found to be associated with the patient's intake of a number of drugs.
Conclusion. polypragmasy has a negative impact on POAC intake. On the one hand it is a factor of decreased adherence to treatment, on the other hand - a factor of undesirable drug interactions.
Keywords
Full Text
About the authors
A. P. Kondrakhin
State Budgetary Institution of Healthcare of Moscow "Hospital for War Veterans No. 2 of the Moscow City Health; Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation Department
Author for correspondence.
Email: 79104851199@yandex.ru
ORCID iD: 0000-0002-3439-8059
Ph.D. (Med.), Chief Specialist of the Moscow City Health Department for Clinical Pharmacology of the South-Eastern Administrative District of Moscow; Clinical Pharmacologist; Senior Lecturer of the Pharmacology Department of the Institute of Pharmacy and Medical Chemistry
Russian Federation, Volgogradsky Prospekt, 168, Moscow, 109472; st. Ostrovityanova, 1, Moscow, 117513M. L. Maksimov
Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation; Kazan State Medical Academy - branch of the Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation; Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation
Email: maksim_maksimov@mail.ru
ORCID iD: 0000-0002-8979-8084
Dr.Sc. (Med.), Professor, Head of the Department of Clinical Pharmacology and Pharmacotherapy; Professor of the Department of Pharmacology of the Institute of Physics and Metabolism; Dean of the Faculty of Preventive Medicine and Healthcare Organization
Russian Federation, st. Ostrovityanova, 1, Moscow, 117513; Butlerova street, 36, Tukay square, Kazan, 420012, Republic of Tatarstan; 2/1, building 1, Barrikadnaya st., Moscow, 125993I. V. Sychev
Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation
Email: sychev_iv@bk.ru
ORCID iD: 0000-0003-0227-2651
Junior Research Scientist, Research Institute of Molecular and Personalized Medicine
Russian Federation, 2/1, building 1, Barrikadnaya st., Moscow, 125993References
- Максимов М.Л., Бонцевич Р.А., Бурашникова И.С. и др. Клиническая фармакология и рациональная фармакотерапия для практикующих врачей: учебник.; под ред. проф. М.Л. Максимова. Казань: ИД «МеДДоК». 2021; 948 с.[Maksimov M.L., Boncevich R.A., Burashnikova I.S. i dr. Klinicheskaja farmakologija i racional'naja farmakote-rapija dlja praktikujushhih vrachej: uchebnik.; pod red. prof. M.L. Maksimova. Kazan': ID «MeDDoK». 2021; 948 s. (In Russ.)]
- Ermakov D., Fomina E., Kartashova O. Specific features of rational pharmacotherapy in elderly patients. Eur J Hosp Pharm. 2023; 30(6): 322–327. doi: 10.1136/ejhpharm-2021-002980.
- Adamiak-Giera U., Nowak A., Duchnik W., et al. Evaluation of the in vitro permeation parameters of topical ketoprofen and lidocaine hydrochloride from transdermal Pentravan® products through human skin. Front Pharmacol. 2023; 14: 1157977. doi: 10.3389/fphar.2023.1157977.
- Alexander K.P., Brouwer M.A., Mulder H., et al. Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. Am Heart J. 2019; 208: 123–131. doi: 10.1016/j.ahj.2018.09.017.
- Rosemann A., Senn O., Neuner-Jehle S., et al. New/direct oral anticoagulants (DOAK). Praxis (Bern 1994). 2023; 112(13): 616–627.
- Van der Linden L., Vanassche T., Van Cutsem E., et al. Pharmacokinetic drug-drug interactions with direct anticoagulants in the management of cancer-associated thrombosis. Br J Clin Pharmacol. 2023; 89(8): 2369–2376. doi: 10.1111/bcp.15785.
Supplementary files
